Vor Biopharma Inc. (VOR)
VOR moved a median of -0.04% 30 minutes after news, and -1.24% by the close. How VOR actually reacts to news — the realized, point-in-time move the market made, measured across 390 labeled events over the last three years with zero look-ahead.
VOR’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.20% | 53% | 389 |
| 30-min | -0.04% | 48% | 390 |
| 60-min | -0.41% | 42% | 390 |
| to close | -1.24% | 42% | 388 |
| Middle 50% of VOR reactions | -2.55% to +2.37% |
|---|---|
| Median reaction (30-min) | -0.04% |
| Measured reactions | 390 |
Half of all Vor Biopharma Inc. news events land between -2.55% and +2.37% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How VOR reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 19 | +1.03% | 53% | -0.03% |
| Analyst downgrades | 14 | -9.19% | 36% | -3.53% |
| Coverage initiations | 16 | +0.15% | 56% | +1.31% |
| Rating reiterations | 59 | +0.29% | 58% | +0.59% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how VOR ranks against every other measured name →
That’s how VOR usually reacts — get an email when it moves on news →Email me when VOR moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to VOR's baseline. Nothing else.
Recent VOR events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -2.23% | -2.87% | |
| Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis | Press release | GlobeNewswire | -0.07% | -1.61% | |
| Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis | Press release | GlobeNewswire | +0.24% | +2.32% | |
| Form S-3ASR Vor Biopharma Inc. | SEC filing · Form S-3ASR | SEC EDGAR | +0.24% | +2.32% | |
| Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.24% | +2.32% | |
| Vor Bio To Participate in Upcoming September Conferences | Press release | GlobeNewswire | +1.37% | +1.43% | |
| Form 10-Q Vor Biopharma Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.35% | +2.39% | |
| Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -1.36% | +2.06% | |
| Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.23% | +3.25% | |
| Form 8-K Vor Biopharma Inc. For: Jul 06 | SEC filing · Form 8-K | SEC EDGAR | +1.26% | +2.58% | |
| Vor Bio Appoints David Zaccardelli to Board of Directors | Press release | GlobeNewswire | +1.26% | +2.58% | |
| Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.22% | -1.85% | |
| Form 8-K Vor Biopharma Inc. For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | +1.36% | -4.61% | |
| Form 8-K Vor Biopharma Inc. For: Jun 08 | SEC filing · Form 8-K | SEC EDGAR | -1.05% | -0.45% | |
| Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China | Press release | GlobeNewswire | -1.32% | -2.28% | |
| Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China | Press release | GlobeNewswire | -1.32% | -2.28% | |
| Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.15% | -4.88% | |
| Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference | Press release | GlobeNewswire | -2.07% | -2.97% | |
| Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine | Press release | GlobeNewswire | -7.68% | -6.63% | |
| Form 10-Q Vor Biopharma Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.86% | -1.97% | |
| Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.86% | -1.97% | |
| Form EFFECT Vor Biopharma Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.50% | +1.13% | |
| Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.20% | +4.72% | |
| Form ARS Vor Biopharma Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +3.87% | +2.94% | |
| Form DEF 14A Vor Biopharma Inc. For: Apr 23 | SEC filing · Form DEF | SEC EDGAR | +3.87% | +2.94% | |
| Form DEFA14A Vor Biopharma Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +3.87% | +2.94% | |
| Form S-3 Vor Biopharma Inc. | SEC filing · Form S-3 | SEC EDGAR | +3.87% | +2.94% | |
| Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.43% | +7.50% | |
| Form 10-K Vor Biopharma Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.06% | +0.27% | |
| Form S-8 Vor Biopharma Inc. | SEC filing · Form S-8 | SEC EDGAR | +1.06% | +0.27% | |
| Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease | Press release | GlobeNewswire | +1.06% | +0.27% | |
| Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +1.06% | +0.27% | |
| Form 8-K Vor Biopharma Inc. For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | +0.75% | +6.00% | |
| Vor Bio Announces $75 Million Private Placement with TCGX | Press release | GlobeNewswire | +0.75% | +6.00% | |
| Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -2.34% | -2.10% | |
| Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference | Press release | GlobeNewswire | +2.40% | +13.80% | |
| Form EFFECT Vor Biopharma Inc. | SEC filing · Form EFFECT | SEC EDGAR | -0.81% | -1.71% | |
| Form S-3 Vor Biopharma Inc. | SEC filing · Form S-3 | SEC EDGAR | +0.21% | -10.65% | |
| Form 8-K Vor Biopharma Inc. For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | +0.11% | +0.11% | |
| Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | -1.78% | +9.06% | |
| Form 8-K Vor Biopharma Inc. For: Dec 31 | SEC filing · Form 8-K | SEC EDGAR | -0.17% | -11.24% | |
| Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors | Press release | GlobeNewswire | +2.00% | +7.63% | |
| Form 8-K Vor Biopharma Inc. For: Dec 15 | SEC filing · Form 8-K | SEC EDGAR | +2.55% | -3.95% | |
| Vor Bio Announces $150 Million Private Placement | Press release | GlobeNewswire | +2.89% | +5.55% | |
| Form 8-K Vor Biopharma Inc. For: Dec 05 | SEC filing · Form 8-K | SEC EDGAR | -7.31% | +1.71% | |
| Form 8-K Vor Biopharma Inc. For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | +3.80% | +0.60% | |
| Form S-3/A Vor Biopharma Inc. | SEC filing · Form S-3 | SEC EDGAR | +4.63% | +3.47% | |
| Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock | Press release | GlobeNewswire | +4.63% | +3.47% | |
| Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock | Press release | GlobeNewswire | +4.63% | +3.47% | |
| Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China | Press release | GlobeNewswire | +2.40% | -2.13% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the VOR section they belong to.
Where else VOR is measured.
VOR earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Vor Biopharma Inc.'s median reaction calculated?
Every labeled VOR news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 390 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of VOR's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does VOR's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.